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The Change in Baseline IMDC Prognostic Category:
From the Past, Implications for the FutureWe read with interest the paper by Davis and colleagues [1]
about the different outcomes for second-line of therapy
according to changes in prognostic class for patients with
metastatic renal cell carcinoma (mRCC). This paper has at
least three important points that need to be highlighted.
First is the evidence that among mRCC patients, worsening
of prognosis is more frequent than improvement. Second, as
a consequence of the first point, is the evidence that
prognosis is a dynamic parameter in mRCC and should be
re-evaluated for each new line of therapy. Third, these
findings may suggest a tailored approach when choosing a
new line of therapy.
If this is true, is the evidence reported also useful in the
new era of immunotherapy andMET/VEGFR tyrosine kinase
inhibitors (TKIs)?
In this context, the prognostic class at the beginning of
second-line therapy is a cornerstone in choosing the
therapy sequence at present, when immunotherapy and
the new generation of TKIs have both shown an increase in
overall survival (OS) when used as second-line therapy
[2,3]. The authors reported that patients with a prognostic
improvement had a better outcome using a second TKI,
while no difference was found for patients with no change
or worsening of the prognostic class. Similarly, recent
second-line phase 3 trials with cabozantinib and nivolumab
reported that the International Metastatic Renal Cell
Carcinoma Database Consortium (IMDC) classification
retained its prognostic role. In clinical practice it is evident
that patients with good prognosis at the beginning of
second-line therapy experience longer survival and a higherDOI of original article: http://dx.doi.org/10.1016/j.eururo.2016.09.047.
http://dx.doi.org/10.1016/j.eururo.2016.12.012
0302-2838/# 2016 European Association of Urology. Published by Elsevierprobability of receiving further lines compared to other
prognostic groups. Put simply, these patients have a strong
probability of receiving both cabozantinib and nivolumab,
but there are neither prospective nor retrospective studies
on the sequence of these therapies to guide treatment
choices. Considering that patients with a proven response
and good tolerability to the first VEGFR TKI might be
preferred for another linewith a second VEGFR/MET TKI, the
lack of a significant OS benefit in the good prognostic group
for nivolumab in the Checkmate-025 trial, and the higher
risk of progression as the best response for nivolumab (35%)
compared to cabozantinib (14%) should be borne in mind
[[1_TD$DIFF]2,3]. Unfortunately, recent clinical trials have reported that
only 40% of patients have good prognosis at the beginning of
second-line therapy, and this group might be smaller in
clinical practice, while no evidence is available for other
prognostic groups.
Finally, although this study was performed in a popula-
tion not representative of future second-line treatments, it
remains interesting because of the prognostic role of IMDC
classification, which is independent of the type of treatment
used and has implications for an evolving scenario moving
from TKI versus mTOR to TKI versus immunotherapy.
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